QSAM Biosciences, Inc. Warrant (QSAMW) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
QSAM Biosciences, Inc. Warrant (QSAMW). QSAM Biosciences, Inc. is a clinical-stage biotechnology company focused on developing radiopharmaceutical therapies for cancer. Their lead candidate, CycloSam, targets bone metastases and is currently in clinical trials. Sector: Healthcare.
Last analyzed: Mar 18, 2026Not enough scored data yet to form a council read on QSAMW.
How is this calculated? →QSAM Biosciences, Inc. Warrant (QSAMW) Healthcare & Pipeline Overview
QSAM Biosciences, Inc. is a clinical-stage biotech firm specializing in radiopharmaceutical therapies, particularly CycloSam for bone metastases. Currently undergoing clinical trials, QSAMW aims to address unmet needs in cancer treatment, focusing on targeted radionuclide therapy within the biotechnology sector.
What Is the Investment Thesis for QSAMW?
QSAM Biosciences presents an investment opportunity within the radiopharmaceutical sector, driven by its lead candidate, CycloSam, targeting bone metastases. The company's value hinges on the successful completion of ongoing clinical trials and subsequent regulatory approvals. Key value drivers include the demonstration of CycloSam's efficacy and safety in Phase 2 and Phase 3 trials, which could lead to accelerated market adoption. Upcoming catalysts involve clinical trial readouts and potential partnerships with larger pharmaceutical companies. However, potential risks include clinical trial failures, regulatory hurdles, and competition from existing and emerging cancer therapies. Investor returns will depend on QSAM's ability to navigate these challenges and successfully commercialize CycloSam.
Based on FMP financials and quantitative analysis
QSAMW Key Highlights
CycloSam is QSAM's lead candidate, a bone-targeting radiopharmaceutical in clinical development for bone metastases.
- QSAM is focused on addressing unmet needs in cancer treatment through targeted radionuclide therapy.
- The company is based in Austin, Texas, and collaborates with academic institutions and CROs.
- QSAM's strategy involves internal R&D and strategic partnerships to accelerate drug development.
- QSAM aims to establish CycloSam as a standard-of-care treatment for patients with bone metastases.
Who Are QSAMW's Competitors?
QSAMW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
| RPRX Royalty Pharma plc | $60.58 | -1.86% | $26.9B | 75 |
| INCY Incyte Corporation | $127.80 | -0.53% | $25.9B | 99 |
| UTHR United Therapeutics Corporation | $520.23 | -1.68% | $22.1B | 98 |
| NBIX Neurocrine Biosciences, Inc. | $153.42 | -1.37% | $15.4B | 93 |
| EXEL Exelixis, Inc. | $53.69 | -1.29% | $13.5B | 98 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are QSAMW's Key Strengths?
Proprietary radiopharmaceutical technology
- Clinical-stage lead candidate (CycloSam)
- Focus on unmet needs in cancer treatment
- Experienced management team
What Are QSAMW's Weaknesses?
Limited financial resources
- Reliance on a single drug candidate
- Lack of commercialization experience
- High regulatory hurdles
What Could Drive QSAMW Stock Higher?
Clinical trial readouts for CycloSam in Phase 2 studies.
- Potential partnerships with pharmaceutical companies for CycloSam development and commercialization.
- Advancements in manufacturing and delivery processes for CycloSam.
What Are the Key Risks for QSAMW?
Clinical trial failures for CycloSam.
- Regulatory delays or rejections for CycloSam.
- Competition from existing and emerging cancer therapies.
- Dependence on successful clinical trials and regulatory approvals for CycloSam.
What Are the Growth Opportunities for QSAMW?
- Expansion of CycloSam's indications: QSAM Biosciences has the opportunity to expand the use of CycloSam beyond its initial target of bone metastases to other cancer types that involve bone involvement. This could significantly increase the addressable market and revenue potential for the company. The market for cancer therapies is projected to reach $200 billion by 2028, providing a substantial opportunity for QSAM to capture market share with CycloSam.
- Strategic partnerships and collaborations: QSAM can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of CycloSam. Collaborations can provide access to additional resources, expertise, and distribution networks, enhancing QSAM's ability to bring its product to market effectively. The timeline for establishing such partnerships is estimated to be within the next 1-2 years.
- Development of novel radiopharmaceutical candidates: QSAM can leverage its expertise in radiopharmaceutical development to create new candidates targeting different types of cancer. This would diversify the company's pipeline and reduce its reliance on a single product. The radiopharmaceutical market is expected to grow at a CAGR of 10% over the next five years, driven by advancements in targeted therapies.
- Geographic expansion: QSAM has the potential to expand its geographic reach beyond the United States to international markets. This would require navigating regulatory approvals in different countries but could significantly increase the company's revenue potential. The global market for cancer therapies is estimated to be worth $150 billion, with significant growth opportunities in emerging markets.
- Advancements in manufacturing and delivery: QSAM can invest in improving the manufacturing and delivery processes for CycloSam to enhance its efficiency and reduce costs. This could involve developing new formulations or delivery methods that improve the drug's bioavailability and targeting capabilities. Innovations in drug delivery technologies are expected to drive growth in the pharmaceutical industry over the next decade.
What Are QSAMW's Competitive Advantages?
- Proprietary radiopharmaceutical technology.
- Patent protection for its drug candidates.
- Clinical data supporting the efficacy and safety of its therapies.
- Established relationships with academic institutions and CROs.
What Does QSAMW Do?
QSAM Biosciences, Inc., is a clinical-stage biotechnology company dedicated to developing and commercializing next-generation therapeutic radiopharmaceuticals for the treatment of cancer. The company's core focus is on CycloSam (Samarium-153 DOTMP), a clinical-stage bone-targeting radiopharmaceutical. CycloSam has shown potential in preclinical and clinical studies to selectively target and destroy cancer cells in bone, addressing a significant unmet need in patients with bone metastases. Founded with the mission to improve the lives of cancer patients, QSAM Biosciences is committed to advancing its pipeline of radiopharmaceutical candidates through rigorous clinical trials and strategic partnerships. The company aims to establish CycloSam as a standard-of-care treatment option for patients with various types of cancer that have metastasized to the bone. QSAM Biosciences is headquartered in Austin, Texas. The company's strategy involves a combination of internal research and development efforts, as well as collaborations with leading academic institutions and contract research organizations (CROs) to accelerate the development and commercialization of its radiopharmaceutical therapies. QSAM Biosciences is working to expand the applications of CycloSam to other cancer types and explore new radiopharmaceutical candidates to broaden its oncology portfolio.
What Products and Services Does QSAMW Offer?
- Develops radiopharmaceutical therapies for cancer treatment.
- Focuses on bone-targeting radiopharmaceuticals.
- Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Collaborates with academic institutions and CROs.
- Aims to commercialize its radiopharmaceutical therapies.
- Works to expand the applications of its therapies to other cancer types.
- Engages in internal research and development efforts.
How Does QSAMW Make Money?
- Develops and patents radiopharmaceutical therapies.
- Conducts clinical trials to gain regulatory approval.
- Commercializes approved therapies through direct sales or partnerships.
- Generates revenue from product sales and licensing agreements.
What Industry Does QSAMW Operate In?
The biotechnology industry is characterized by intense research and development, high regulatory hurdles, and significant capital requirements. The radiopharmaceutical market, in particular, is experiencing growth due to advancements in targeted therapies and imaging techniques. Companies like QSAM Biosciences are positioned to capitalize on this trend by developing innovative radiopharmaceuticals for cancer treatment. The competitive landscape includes established pharmaceutical companies and specialized biotech firms focused on oncology. Success in this industry requires strong scientific expertise, efficient clinical trial execution, and strategic commercialization capabilities.
Who Are QSAMW's Key Customers?
- Hospitals and cancer treatment centers.
- Oncologists and other healthcare professionals.
- Patients with cancer, particularly bone metastases.
Key Financial Metrics
A current ratio of 1.65 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -15.0%, the inverse of the P/E and a quick read on earnings relative to price.
QSAMW Financials
Bull Case vs Bear Case
Bull Case
- Proprietary radiopharmaceutical technology
- Clinical-stage lead candidate (CycloSam)
- Focus on unmet needs in cancer treatment
- Experienced management team
Bear Case
- Limited financial resources
- Reliance on a single drug candidate
- Lack of commercialization experience
- High regulatory hurdles
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
QSAMW Latest News
No recent news available for QSAMW.
QSAMW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for QSAMW.
Price Targets
Wall Street price target analysis for QSAMW.
QSAMW MoonshotScore
What does this score mean?
The MoonshotScore rates QSAMW 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
QSAM Biosciences, Inc. Warrant Healthcare Stock: Key Questions Answered
What does QSAMW do?
QSAM Biosciences, Inc. is a clinical-stage biotechnology company focused on developing and commercializing radiopharmaceutical therapies for the treatment of cancer. Their lead candidate, CycloSam (Samarium-153 DOTMP), is a bone-targeting radiopharmaceutical currently in clinical development for the treatment of bone metastases.
What are the main risks for QSAMW?
The main risks for QSAM Biosciences include clinical trial failures, regulatory hurdles, and competition from existing and emerging cancer therapies. Clinical trial failures could significantly delay or halt the development of CycloSam. Regulatory delays or rejections could also impact the company's ability to bring its product to market.
What are the key factors to evaluate for QSAMW?
Evaluate QSAMW on fundamentals, analyst consensus, and risk factors. QSAM Biosciences presents an investment opportunity within the radiopharmaceutical sector, driven by its lead candidate, CycloSam, targeting bone metastases. Not financial advice.
How frequently does QSAMW data refresh on this page?
QSAMW prices refresh on page view and on a rolling daily schedule; the last-updated date appears near the top of this page. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven QSAMW's recent stock price performance?
QSAM Biosciences, Inc. Warrant (QSAMW) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary radiopharmaceutical technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider QSAMW overvalued or undervalued right now?
QSAM Biosciences, Inc. Warrant (QSAMW) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research QSAMW before investing?
Before investing in QSAM Biosciences, Inc. Warrant (QSAMW), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding QSAMW to a portfolio?
Key strength of QSAM Biosciences, Inc. Warrant (QSAMW): Proprietary radiopharmaceutical technology. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending for QSAMW.